The notion that GLP-1 analogues may affect feeding even when they do not enter the brain is supported by studies showing that large molecular size GLP-1 receptor agonists (albumin-conjugated GLP-1 receptor agonists), that cannot cross the blood-brain barrier can inhibit feeding in both humans and mice
Then evaluate protein intake (increase to 1.0 to 1.2 g/kg), exercise habits (add or intensify resistance training), sleep quality, stress levels, and alcohol consumption
Capitalizing on this, a ruthenium complex with an iodo, p-cymene, and phenylazopyridine ligand Ru(II)-OH was designed
The remaining third of the EDTA-treated plasma was stored at 4 o C without prior deproteinization and was deproteinized immediately prior to analysis
However, the results remain inconclusive, and more clinical research is needed to confirm its potential benefits in addiction treatment